Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. Founded in 2017, Tango is focused on harnessing the power of synthetic lethality to discover and develop precision oncology therapies. By identifying tumor-specific genetic dependencies, the company aims to create targeted treatments that exploit vulnerabilities unique to cancer cells while sparing healthy tissues.
The company’s proprietary discovery engine integrates CRISPR-based genome-wide screening with advanced computational biology to pinpoint novel synthetic lethal interactions. Tango’s pipeline includes multiple wholly owned programs targeting DNA damage repair pathways, as well as immuno-oncology and metabolic vulnerabilities. Lead assets are advancing through preclinical validation and into early-stage clinical trials, with several IND submissions anticipated in the coming years.
Tango has forged strategic collaborations with leading pharmaceutical partners to co-develop select programs and expand its therapeutic reach. These alliances leverage Tango’s expertise in target identification alongside partners’ clinical development and commercialization capabilities. The company is led by CEO Debora Barton, Ph.D., whose leadership team brings deep experience in oncology drug discovery, translational research and global biopharmaceutical operations.
Operating primarily in the United States, Tango maintains research and development facilities in Kendall Square and collaborates with academic institutions and contract research organizations worldwide. Committed to advancing next-generation cancer medicines, the company’s mission is to deliver differentiated therapies that offer new treatment options for patients with high unmet medical need across diverse tumor types.
AI Generated. May Contain Errors.
